9月14日，葛兰素史克盘前上涨3.32%，报49.73美元/股，成交额84.86万美元。
消息面上，GSK在首尔世界肺癌大会上公布了注册性I/II期ARROS-1试验最新数据：在94名未接受过TKI治疗的ROS1阳性非小细胞肺癌患者中，Jideytro实现94%的客观缓解率，其中15%达到完全缓解，远超同类ROS1抑制剂5%-7%的完全缓解率。此外，所有脑转移患者均对治疗产生应答，70%实现脑部肿瘤完全清除。安全性方面，仅11%患者因不良事件减量、1%停药。公司计划年内向FDA提交一线适应症扩展申请。Jideytro是GSK首个商业化肺癌药物，此前已获FDA批准用于经治ROS1阳性肺癌，一线数据的强劲表现为其"重磅炸弹级"销售潜力提供了有力支撑。
（以上内容均基于市场公开消息，由程序或算法智能生成，仅作为股价异动提醒，不作为投资建议或交易依据。）
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.